Involvement of the cGMP signalling pathway in the regulation of viability in insulin-secreting BRIN-BD11 cells.
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival; D006152:Cyclic GMP / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000502:physiology*; D062965:Cyclic GMP-Dependent Protein Kinase Type I; D062967:Cyclic GMP-Dependent Protein Kinase Type II; D017869:Cyclic GMP-Dependent Protein Kinases / Q000187:drug effects / Q000502:physiology*; D003609:Dactinomycin / Q000494:pharmacology; D006162:Guanylate Cyclase / Q000187:drug effects; D007191:Indazoles / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000166:cytology* / Q000378:metabolism; D020033:Protein Isoforms / Q000032:analysis; D051381:Rats; D015398:Signal Transduction / Q000502:physiology*; D013873:Thionucleotides / Q000494:pharmacology; D014158:Transcription, Genetic
C090860:8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate; D007191:Indazoles; D007328:Insulin; D020033:Protein Isoforms; D013873:Thionucleotides; C090937:3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole; D003609:Dactinomycin; D062965:Cyclic GMP-Dependent Protein Kinase Type I; D062967:Cyclic GMP-Dependent Protein Kinase Type II; D017869:Cyclic GMP-Dependent Protein Kinases; C569718:PRKG1 protein, human; C569729:PRKG2 protein, human; C569732:Prkg2 protein, rat; D006162:Guanylate Cyclase; D006152:Cyclic GMP